Was it the inability to help this patient which was maybe instrumental in pushing PAA to instigate research into developing a liquid version of MPL?. MT mentioned that this program was started not long after he joined PAA, so a few months ago at least.
It was highlighted in the quarterly that this poor person was part of cohort 1 and thus on the lower dose. Maybe a hint that if a higher dose (liquid or tablet) were possible that they may of been able to help more. I don't know.
Was it the inability to help this patient which was maybe...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
-0.010(5.41%) |
Mkt cap ! $69.28M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 18.5¢ | 17.5¢ | $58.74K | 325.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 270003 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 116651 | 3 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
18.0¢ |
Change
-0.010 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 18.0¢ | 18.0¢ | 17.5¢ | 141605 | ||
| Last updated 15.28pm 21/05/2024 ? | |||||
| PAA (ASX) Chart |